Shield Therapeutics (Shield), an independent pharmaceutical company focused on the development of specialist hospital pharmaceuticals announced the online publication of the manuscript of the AEGIS Feraccru (ST10, ferric maltol) Phase III pivotal study in the latest edition of the Inflammatory Bowel Disease Journal, the official journal of the Crohn’s and Colitis Foundation of America.
Dr Julian Howell, Group Medical Director and VP Drug Development, commented:
Shield Therapeutics (Shield), an independent pharmaceutical company focused on the development of specialist hospital pharmaceuticals announced the online publication of the manuscript of the AEGIS Feraccru (ST10, ferric maltol) Phase III pivotal study in the latest edition of the Inflammatory Bowel Disease Journal, the official journal of the Crohn’s and Colitis Foundation of America.
Dr Julian Howell, Group Medical Director and VP Drug Development, commented:
“This peer-reviewed manuscript is an excellent portrayal of the potential, the features and the benefits of Feraccru and we look forward to further developing this important asset for the benefit of patients who cannot tolerate oral ferrous iron and so have to rely on the higher risk option of invasive and resource-consuming intravenous iron administration.”
This announcement follows the recent news that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Feraccru, a novel orally delivered form of ferric iron, for review. Shield is seeking marketing authorisation of Feraccru for the treatment of iron deficiency anaemia (IDA), initially in patients with inflammatory bowel disease (IBD) and those intolerant of oral ferrous therapies, thereby providing an effective alternative to those patients whose only current option is intravenous iron therapy.
